Many learners are more facile with the use of large language models in medicine than their supervisors are. The authors ...

A 28-year-old woman was admitted to the hospital because of severe hypoxemia and right heart failure that had been caused by ...

The FDA has begun soliciting feedback to inform the next version of the Prescription Drug User Fee Act. User fees remain ...

In this phase 3, double-blind, placebo-controlled trial, we randomly assigned patients with aPAP to receive molgramostim at a dose of 300 μg or placebo once daily for 48 weeks. The primary end ...

MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as pharmacotherapies targeting the associated liver and cardiovascular ...

Neoadjuvant nivolumab plus chemotherapy has previously been shown to improve pathological response in resectable non–small-cell lung cancer. New research findings on overall survival at 5 years ...

A 32-year-old woman presented with fatigue, myalgias, and palpitations. The cardiac rhythm was irregularly irregular, and an electrocardiogram showed findings suggestive of grouped beating. A diagn ...

In this trial involving women taking endocrine therapy for HR-positive breast cancer, elinzanetant (a neurokinin-targeted therapy) significantly reduced the frequency of moderate- ...

Risdiplam, an oral pre–messenger RNA splicing modifier, is an efficacious treatment for persons with symptomatic spinal muscular atrophy (SMA). The safety and efficacy of risdiplam in ...

Inhaled molgramostim showed promise for treating patients with autoimmune pulmonary alveolar proteinosis in an early trial. New research findings from a phase 3 trial are summarized in a short video.

In this randomized trial, the inhaled recombinant human GM-CSF molgramostim improved pulmonary gas transfer in patients with autoimmune pulmonary alveolar proteinosis.